Use of PEDF-derived polypeptides for treating liver cirrhosis
AssigneeMackay Memorial Hospital
InventorsShou-Chuan Shih, Yeou-Ping Tsao, Tsung-Chuan Ho
Life of this patent
Estimating the term…
Abstract
The present disclosure elucidates that 34-mer PEDF suppresses hepatic stellate cells (HSCs) from activation by diminishing the levels of alpha-smooth muscle actin (α-SMC), collagen type 1, and monocyte chemoattractant protein-1 (MCP-1); and 44-mer PEDF promotes liver regeneration process by enhancing the replication of liver-derived progenitor cells (LDPCs). Accordingly, methods and compositions directing to the new use of the 34-mer PEDF or 44-mer PEDF in patients suffering from liver cirrhosis are provided herein.
Claims7
A method of treating liver cirrhosis in a mammalian subject comprising administering to the subject in need thereof a polypeptide having 34 amino acid residues in length and the amino acid sequence of SEQ ID NO:
- 1, wherein the polypeptide is capable of inactivating hepatic stellate cells (HSCs).
A method of treating liver cirrhosis in a mammalian subject comprising administering to the subject in need thereof a polypeptide having 44 amino acid residues in length and the amino acid sequence of SEQ ID NO:
- 2, wherein the polypeptide is capable of enhancing the replication of liver-derived progenitor cells (LDPCs).
Dependencies are inferred from the claim text.